10-K/A: Qualis Innovations Files Amended 10-K, Cites Material Weaknesses in Internal Controls and Going Concern Uncertainty

Qualis Innovations, Inc. has filed an amended annual report on Form 10-K/A, highlighting material weaknesses in internal controls, an impairment of assets, and substantial doubt about the company's ability to continue as a going concern.

Summary

• Qualis Innovations, Inc. filed an amendment to its annual report on Form 10-K, primarily to reflect that it is not an emerging growth company and to amend details regarding internal controls and board appointments.
• The company reported a net loss of $805,021 for the year ended December 31, 2023, compared to a net loss of $920,515 in 2022.
• Operating expenses decreased significantly to $230,241 in 2023 from $920,515 in 2022, mainly due to reduced stock-based compensation, consulting, and professional fees.
• The company recognized an impairment of assets totaling $76,008 in 2023 due to a third-party manufacturer's inability to deliver the remaining SOLACE devices.
• Qualis has an accumulated deficit of $4,430,308 as of December 31, 2023, and a working capital deficit of $522,956, raising substantial doubt about its ability to continue as a going concern.
• The company's cash position is weak, with only $2,431 in cash as of December 31, 2023.
• Qualis is developing a pain management device called SOLACE, but it has not yet finalized development or generated any cash flows from operations.
• The company is preparing to submit an application to the FDA for clearance of the SOLACE device.
• The company has issued 10,000,000 common shares valued at $500,000 to two affiliates in settlement of a dispute and 2,000,000 common shares to two affiliates for $100,000 in January 2024.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with significant losses, a large accumulated deficit, and a going concern warning. While there are some positive aspects, such as reduced operating expenses, the overall sentiment is negative due to the company's financial instability and operational challenges.

Positives

• The company reduced its operating expenses significantly in 2023.
• The net loss for 2023 was lower than the net loss for 2022.
• The company is actively working towards FDA clearance for its SOLACE device.

Negatives

• The company has a significant accumulated deficit of $4,430,308.
• The company has a working capital deficit of $522,956.
• The company has very limited cash reserves of only $2,431.
• The company experienced an impairment of assets due to issues with a third-party manufacturer.
• The company has not generated any revenue since inception.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is uncertain due to its accumulated deficit, working capital deficit, and limited cash reserves.
• The company's reliance on a third-party manufacturer poses a risk to its supply chain and product development.
• The company's ability to obtain FDA clearance for its SOLACE device is not guaranteed.
• The company may need to raise additional capital, which may not be available on favorable terms or at all.
• The company faces intense competition in the medical device industry.
• The company has identified material weaknesses in its internal controls over financial reporting.

Future Outlook

The company expects that its current working capital position, together with expected future cash flows from operations, will be insufficient to fund its operations for at least the next twelve months. The company intends to raise additional funds by way of a public offering or an asset sale transaction.

Management Comments

• Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern.
• Management intends to raise additional funds by way of a public offering or an asset sale transaction.

Industry Context

The medical device industry is highly competitive, with many companies developing similar products. Qualis faces competition from larger companies with greater resources. The company's focus on pain management aligns with a growing demand for non-opioid alternatives, but it must navigate regulatory hurdles and market competition to succeed.

Comparison to Industry Standards

• The company's lack of revenue and significant losses are not uncommon for early-stage medical device companies, but the magnitude of the accumulated deficit and the going concern warning are concerning.
• Compared to established medical device companies like Medtronic or Johnson & Johnson, Qualis is significantly smaller and has limited resources.
• The company's reliance on third-party manufacturers is a common practice in the industry, but the recent issues with the manufacturer highlight the risks involved.
• The company's focus on a specific niche market (pain management) is a common strategy for smaller companies to gain a foothold in the industry, but it also limits the potential market size.
• The company's financial metrics are significantly worse than comparable companies in the medical device sector, such as those in the Russell 2000 index.

Management Changes

Corporate Governance

Related Party Transactions

• The company borrows funds from the Companys CEO for working capital purposes from time to time.
• The company issued 10,000,000 common shares valued at $500,000 to two affiliates in settlement of a dispute.
• The company issued 2,000,000 common shares to two affiliates for $100,000.
• The company has entered into indemnification agreements with each of its directors and executive officers.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be impacted by potential cost-cutting measures or restructuring.
• Customers may be affected by delays in product development and availability.
• Suppliers may face uncertainty regarding future orders and payments.
• Creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to submit an application to the FDA for clearance of the SOLACE device.
• The company intends to raise additional funds through a public offering or asset sale.
• The company will continue to evaluate acquisitions of and/or investments in products, technologies, capital equipment or improvements or companies that complement its business.

Key Dates

Keywords

medical device, pain management, SOLACE device, FDA clearance, internal controls, going concern, financial statements, impairment of assets, operating expenses, net loss, share issuance, warrants